Analysts at StockNews.com began coverage on shares of vTv Therapeutics (NASDAQ:VTVT - Get Free Report) in a report released on Wednesday. The brokerage set a "sell" rating on the biotechnology company's stock.
Separately, Alliance Global Partners started coverage on shares of vTv Therapeutics in a report on Monday, December 9th. They issued a "buy" rating and a $35.00 price target on the stock.
Read Our Latest Report on VTVT
vTv Therapeutics Stock Performance
VTVT stock traded down $0.96 during trading on Wednesday, reaching $16.64. 20,028 shares of the company were exchanged, compared to its average volume of 23,070. The company has a market cap of $53.08 million, a P/E ratio of -3.67 and a beta of 1.07. vTv Therapeutics has a 52-week low of $12.12 and a 52-week high of $29.85. The stock's 50 day moving average price is $16.97 and its 200 day moving average price is $15.44.
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The biotechnology company reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($0.87) by $0.32. The company had revenue of $0.02 million for the quarter.
Institutional Trading of vTv Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC lifted its stake in shares of vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company's stock valued at $158,000 after buying an additional 1,327 shares during the period. JPMorgan Chase & Co. purchased a new position in shares of vTv Therapeutics during the fourth quarter valued at approximately $25,000. Finally, FMR LLC purchased a new position in shares of vTv Therapeutics during the third quarter valued at approximately $2,402,000. Hedge funds and other institutional investors own 17.51% of the company's stock.
vTv Therapeutics Company Profile
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
See Also
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
